
-
Trump arrives in Britain for unprecedented second state visit
-
FBI chief spars with Democrats in heated Senate hearing
-
'A better future is possible': Youths sue Trump over climate change
-
Redford's Sundance legacy 'beyond comprehension' for US filmmakers
-
Vuelta protests 'a completely new phenomenon', says Tour de France director
-
Bangladesh beat Afghanistan to stay alive in Asia Cup
-
Trump extends delay on US TikTok ban until mid-December
-
YouTube ramps up AI tools for video makers
-
Arsenal subs snatch win in Bilbao Champions League opener
-
Downton Abbey auction of props and costumes smashes estimates
-
Windsor prepares for global spotlight with Trump state visit
-
Suspect in Charlie Kirk killing charged with murder
-
France duo out of Women's Rugby World Cup semi-final as bans upheld
-
Simeone backs Atletico to hurt 'extraordinary' Liverpool
-
IEA says more oil and gas investment may be needed
-
Sabrina Carpenter, Justin Bieber, Karol G to headline Coachella
-
Colombia halts US arms purchases in row over drug fight delisting
-
Nestle says chairman Paul Bulcke to step down
-
Isak set for Liverpool debut in Atletico Madrid Champions League clash
-
Malawi votes in economic gloom as two presidents battle for power
-
No info in files that Epstein trafficked women to others: FBI chief
-
Stocks slip, dollar down as Fed meets on rates
-
Faith Kipyegon: Supreme Kenyan champion and role model for mothers
-
Hollywood giants sue Chinese AI firm over copyright infringement
-
Bayern's Kane keen to rekindle London rivalry against Chelsea
-
Trump sues NYT for $15 bn in latest attack on media
-
IndyCar reveals 17-race 2026 season with March opening
-
Trump heads for landmark state visit with 'friend' King Charles
-
Kipyegon sparkles, Tinch's time away pays off with world gold
-
Kerr completes Kiwi world double after Beamish tonic
-
US Fed opens key meeting after Trump aide sworn in as governor
-
Tinch crowns atypical path to top with world hurdles gold
-
Masters deal with Amazon Prime boosts US TV coverage hours
-
Thyssenkrupp says India's Jindal Steel makes bid for steel business
-
Germans turn to health apps as insurers foot the bill
-
Robert Redford, Hollywood's golden boy with a Midas touch
-
US retail sales beat expectations in August despite tariffs
-
New Zealand's Kerr wins world men's high jump gold
-
American Cordell Tinch wins world 110m hurdles gold
-
Kenya's Kipyegon wins unprecedented fourth women's world 1,500m title
-
Suspect in Kirk killing to be charged in US court
-
Cinema legend Robert Redford dead at 89
-
Europe slow to match economic rivals US, China: Draghi
-
Rugby World Cup chiefs defend handling of Berthoumieu biting incident
-
'Like failing a math test': US teen Lutkenhaus schooled at worlds
-
Philippines says one injured in China Coast Guard water cannon attack
-
Kenya court seeks UK citizen's arrest over young mother's murder
-
Malawi votes for a new president as economic crisis bites
-
Barca to stay at Johan Cruyff stadium for Getafe clash
-
'We pulled the children out in pieces': Israel pummels Gaza City

Nobel scientist uncovered tiny genetic switches with big potential
Harvard geneticist Gary Ruvkun vividly remembers the late-night phone call with his longtime friend and now 2024 Nobel Prize in Medicine co-laureate Victor Ambros, when they made their groundbreaking discovery of genetic switches that exist across the tree of life.
It was the early 1990s. The pair, who had met a decade earlier and bonded over their fascination with an obscure species of roundworm, were exchanging datapoints at 11 pm -- one of the rare moments Ambros could steal away from tending to his newborn baby.
"It just fit together like puzzle pieces," Ruvkun told AFP in an interview from his home in a Boston suburb, shortly after learning of the award on Monday. "It was a eureka moment."
What they had uncovered was microRNA: tiny genetic molecules that act as key regulators of development in animals and plants, and hold the promise of breakthroughs in treating a wide range of diseases in the years ahead.
Although these molecules are only 22 "letters" long -- compared to the thousands of lines of code in regular protein-coding genes -- their small size belies their critical role as molecular gatekeepers.
"They turn off target genes," Ruvkun explained.
"It's a little bit like how astronomy starts with looking at the visible spectrum, and then people thought 'If we look with X rays, we can see much higher energy events,'" he added.
"We were looking at genetics at much smaller scales than it had been looked at before."
- Dismissed at first -
Their discovery had its roots in early investigations into C. elegans, a one-millimeter-long roundworm.
Ambros and Ruvkun were intrigued by the interplay between two genes that seemed to disrupt the worm's normal development -- causing them either to stay in a juvenile state or acquire adult features prematurely.
The genetic information contained in all our cells flows from DNA to messenger RNA (mRNA) through a process called transcription, and then on to the cellular machinery where it provides instructions on which proteins to create.
It's through this process, understood since the mid-20th century, that cells become specialized and carry out different functions.
But Ambros and Ruvkun, who began their work in the same lab before moving to different institutions, discovered a fundamentally new pathway for regulating gene activity through microRNAs, which control gene expression after transcription.
They published their findings in back-to-back papers in Cell in 1993, but at first, the discovery was dismissed as an esoteric detail, likely irrelevant to mammals.
"We were considered an oddity in the world of developmental biology," Ruvkun recalled. Even he had little idea their work would one day be celebrated by the wider scientific community.
That all changed in 2000 when Ruvkun's lab discovered another microRNA that was present throughout the tree of life -- from roundworms to mollusks, chickens, and humans.
- 'Celebrating like crazy' -
At the time, the human genome was still being mapped, but the portion that was complete was available to researchers.
"I think it was probably one-third done, and I could already see (the new microRNA) in that one-third of the human genome," said Ruvkun. "That was a surprise!"
Since then, the microRNA field has exploded, with more than 170,000 citations currently listed in biomedical literature.
More than 1,000 microRNAs have been identified in human DNA, and some are already being used to better understand tumor types and develop treatments for people with chronic lymphocytic leukemia.
Trials are also underway to develop microRNAs as treatments for heart disease.
On the morning of their Nobel win, the two old friends "Facetimed and high-fived," Ruvkun said. "It's magnificent, and we're going to be celebrating like crazy."
A.Mahlangu--AMWN